Review
Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept
Affiliations
- PMID: 14730466
Item in Clipboard
Review
Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept
IDrugs.
2004 Jan.
Abstract
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years one of the major foci in psoriasis research has been the development of biological therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention with fewer side effects than traditional therapies. This article will review the progress of four biological agents that are available or under investigation for clinical use: infliximab (Centocor Inc), etanercept (Amgen Inc/Wyeth), efalizumab (Genentech Inc/XOMA Ltd/Serono SA) and alefacept.
Similar articles
-
Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.J Drugs Dermatol. 2005 Sep-Oct;4(5):544-55. J Drugs Dermatol. 2005. PMID: 16167412 Review.
-
An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.Clin Ther. 2003 Oct;25(10):2487-505. doi: 10.1016/s0149-2918(03)80313-2. Clin Ther. 2003. PMID: 14667953 Review.
-
Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.Curr Pharm Des. 2005;11(2):273-80. doi: 10.2174/1381612053382232. Curr Pharm Des. 2005. PMID: 15638763 Review.
-
Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.J Drugs Dermatol. 2002 Dec;1(3):303-10. J Drugs Dermatol. 2002. PMID: 12851990 Review.
-
Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.Br J Dermatol. 2008 Aug;159(2):274-85. doi: 10.1111/j.1365-2133.2008.08673.x. Epub 2008 Jun 10. Br J Dermatol. 2008. PMID: 18547300 Review.
Cited by
-
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Ann Rheum Dis. 2004 Nov;63 Suppl 2(Suppl 2):ii2-ii12. doi: 10.1136/ard.2004.029272. Ann Rheum Dis. 2004. PMID: 15479866 Free PMC article. Review. No abstract available.
-
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv2-14. doi: 10.1136/ard.2005.044941. Ann Rheum Dis. 2005. PMID: 16239380 Free PMC article. Review. No abstract available.
-
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii2-15. doi: 10.1136/ard.2006.061937. Ann Rheum Dis. 2006. PMID: 17038465 Free PMC article. No abstract available.
-
Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece.Clinicoecon Outcomes Res. 2015 Jan 8;7:73-83. doi: 10.2147/CEOR.S75263. eCollection 2015. Clinicoecon Outcomes Res. 2015. PMID: 25609988 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical